Benefit Evaluation of Foot Reflexology in Oncology

Hospices Civils de Lyon80 enrolled

Overview

Chemotherapy with platinum salts is very emetic. The aim of this study is to evaluate the benefits of foot reflexology in nausea and vomiting induced by platinum salts-based chemotherapy in patients with thoracic or digestive tumors.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Lung Cancer and Cancer of Digestive System

Interventions

INTERVIONNALBEHAVIORAL

Foot reflexology session (30 minutes) each course of chemotherapy (total 4 courses) during the 4 hours following the first 2 hours of injection + auto-massage done by the patient between each course. During a session focused on the treatment of nausea / vomiting, the reflexologist will stimulate the reflex zones related to the digestive system in order to calm and stimulate all areas for deep relaxation of the patient.

CONTROLOTHER

None intervention.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with a thoracic or digestive cancer with indication of management with platinum salts-based chemotherapy * Good performance status of (ECOG 0-2) * More than 18 years old * Ability to complete the questionnaires (comprehension oral and written French language) and to carry out the required exercises. * Patient affiliated to Social Security or equivalent * Informed consent signed Exclusion Criteria: * Phlebitis * Cellar syndrome * Weight loss\> 5% in 3 months * Uncontrolled pain * Patients under morphine and derivatives * Brain metastases * Patient benefiting from foot reflexology outside the study * Patient under guardianship or curatorship or deprived of his rights

Locations (1)

Centre Hospitalier Lyon Sud

Pierre-Bénite, France

Outcomes

Primary Outcomes

Evaluation of nausea and vomiting

The relative change in VAS\* associated with nausea and vomiting will be evaluated between T1 (measured at least 2 hours after the start of chemotherapy injection) and T2 (measured at least 6 hours after the start of injection of the drug chemotherapy). \*VAS : from 0 to 10 ; 0 is no nausea or vomiting and 10 is insufferable nausea or vomiting

Time frame: 6 hours

Secondary Outcomes

Nausea and vomiting between each chemotherapy

Between each chemotherapy the patient notes daily whether or not he has had nausea on a notebook.

Time frame: Day 0, between day 14 and day 21, between day 28 and day 42, between day 42 and day 63.

Quality of life

Relative variation of the EORTC QLQC 30\* (European Organisation for Research and Treatment of Cancer) between the inclusion visit (V2) and the end-of-study visit (V6). \*EORTC QLQ C30 : All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

Time frame: Between day 0 and day 78

Anxiety

Relative variation of the HADS\* (Hospital and Anxiety Depression Scale) anxiety score between the inclusion visit (V2) and the end-of-study visit (V6). \*HADS : 0 to 21, the highest scores corresponding to the presence of a more severe symptomatology

Time frame: Between day 0 and day 78

Body image

Evaluation of the body image to the end-of-study visit by the Body Image Questionnaire\* (BIC), which measures the body image at a given moment t. The analysis will take into account the self-esteem assessed upon the inclusion visit on the Rosenberg scale\*\* (V2). \*BIC : The total score is between 19 and 95. \*\*Rosenberg Scale : The total score ranges from 10 to 40. A score below 31 is considered low self-esteem

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.